Mayo Clinic has launched a new SARS-CoV-2 neutralizing antibody test in support of the national Expanded Access Program for Convalescent Plasma and other critical research efforts to establish effective therapies and vaccines for COVID-19.
Thermo Fisher Scientific Inc. announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic.
Mayo Clinic joined Minnesota Gov. Tim Walz, Minnesota Department of Health Commissioner Jan Malcom, the University of Minnesota, and other health system leaders to announce a breakthrough initiative to provide rapid, widespread testing for COVID-19 in Minnesota.
A new serology test from Mayo Clinic Laboratories that is used to identify the presence of immune response to SARS-CoV-2, the virus that causes COVID-19, is now available to more health care organizations.
Mayo Clinic will be the lead institution providing coordinated access to investigational convalescent plasma for hospitalized patients with severe or life-threatening COVID-19, or those at high risk of progression to severe or life-threatening disease. The Food and Drug Administration (FDA) announced the designation on Friday, April 3.
Mayo Clinic has significantly expanded its capacity to test clinical samples for SARS-CoV-2, the virus that causes COVID-19. With new equipment that went online Tuesday, Mayo Clinic Laboratories now has the capacity to process COVID-19 test samples from all Mayo Clinic sites. In addition, it has begun processing test samples from its clients across Minnesota, including eight major health systems.
Mayo Clinic has developed a test that can detect the SARS-CoV-2 virus in clinical samples. The SARS-CoV-2 virus causes COVID-19. The test, “Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2), Molecular Detection” has been fully validated.